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This editorial refers to ‘Impact of the COVID-19 pandemic
on in-hospital mortality in cardiovascular disease: a meta-
analysis’, by A. Cannata et al. doi:10.1093/eurjpc/zwab119.
Coronavirus disease 2019 (COVID-19) pandemic affected every
level of our healthcare systems, especially hospitals, which faced a
huge human and logistical burden. To face the exponential growth of
COVID-19 patients, national or local authorities declared lockdowns
and urged people to avoid seeking medical care for unnecessary
situations. This translated into reductions of hospital admissions,
including for acute problems such as myocardial infarctions.
During the first lockdown, for instance, studies reported a 20–30%
decrease in admissions for myocardial infarction in France or
Denmark.1–3 In New Zealand, despite a low incidence rate of
COVID-19 infections during the first wave, hospitalizations for acute
coronary syndrome also decreased by 28%, especially due to fewer
admissions for non-ST-segment elevation acute coronary syn-
dromes.4 It is also noteworthy that rates of admission for acute cor-
onary syndromes during COVID-19 pandemic were comparable to
pre-pandemic levels in countries that established strict controls of
the epidemics.5,6 Reasons for the reduction in admissions for acute
coronary syndromes are probably multifactorial, but less engagement
in stressful situations due to lockdown is a frequently proposed
explanation. Beyond admission rates during a pandemic situation,
there remains the question of the fate of patients still admitted, espe-
cially those hospitalized with cardiovascular diseases that account
for a large proportion of admissions.
Cannata et al.7 report in the Journal the results of a meta-analysis
comprising studies investigating in-hospital mortality of people admit-
ted with cardiovascular disease but without severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection during the first
wave of the pandemic compared to a pre-pandemic period.
Comprising data from more than 27 000 individuals, their study
showed a 62% higher risk (relative risk) of in-hospital mortality during
the pandemic period. In absolute numbers, mortality amounted to
10.4% during the COVID-19 first wave compared to 5.7% during the
pre-pandemic period. This is in line with large studies conducted at
the level of a country. For instance, in Denmark, a study including 1
113 705 hospital admissions found that the mortality rate ratio
amounted to 1.28 during the first lockdown.3 The meta-analysis by
Cannata et al., including studies from different countries and conti-
nents, adds to the evidence that the pandemic had, and probably still
has in certain settings, a substantial impact on the organization of
hospitals to maintain their level of care to that of the pre-pandemic
context. Consequently, this represents the first ‘sentence’ due to
COVID-19 pandemic for a number of patients with cardiovascular
disease in need of hospital care. This shall inform a range of health-
care professionals and administrators on the effects of reorientating a
substantial part of hospital personal and logistics during such an
endeavour.
One of the main findings of the study is the fact that there exists an
apparent link between a high decline in admission rate (>50%) and an
increased in-hospital mortality rate. This result is derived from three
studies (two conducted in Italy and one in India), representing about
a third of the sample. As postulated by the authors in their limitations,
this could have arisen due to patients’ selection bias, the more fragile
and sicker patients having been admitted during the lockdown. That
could also partially explain the main finding of the study with a strik-
ingly high mortality rate during the COVID-19 period. Nevertheless,
the risk estimate remained consistent when performing sensitivity
analyses, in particular when stratifying by type of cardiovascular dis-
eases with potential differential outcomes (their figure S1). To better
assess any selection bias, additional studies should include hospital
case-mix and illness severity.8
Furthermore, we should bear in mind that comparison between
different countries, health care systems or, even, hospitals within the
same country has important limitations. Cannata et al. stratified by
countries (their figure S5), but the analysis lacked power to detect
any variation. It is also expected that healthcare systems can prove to
be resilient with improvement in care by redirecting resources
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..to non-COVID-19 patients over the time. This has been shown in a
national Danish study with an 8% reduction in in-hospital mortality
rate between the first and second waves.3
As our knowledge on the direct and immediate impacts of
COVID-19 pandemic on health care systems will accrue in the com-
ing months and years, epidemiological and basic research—sup-
ported by funding agencies, especially to allow following cohorts of
patients—shall also investigate the long-term effects of COVID-19 in-
fection on cardiovascular risk factors and disease.9 Indeed, evidence
accumulates on persistent symptoms months after a COVID-19 in-
fection, including in people not hospitalized.10 Capturing the patho-
physiological and population effect of SARS-CoV-2 infection on
development of cardiovascular disease is paramount to avoid a se-
cond ‘sentence’ for patients and ensure that all therapeutic and pre-
ventive measures currently in place continue to maintain their effects.
In conclusion, the study by Cannata et al. highlights the fragility of
our healthcare systems when confronted to such a systemic threat
with direct impacts on the health of hospitalized patients. Further ini-
tiatives should focus on better preparing our hospitals to face diverse
medical conditions in a pandemic situation and, in the context of
COVID-19 pandemic, mitigating the potential long-term effects of
COVID-19 on cardiovascular health.
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